UC2288
Based on 9 publication(s) in Google Scholar
UC2288 is a potent and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 potently inhibits cancer cell growth by inducing apoptosis. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.78%
- CAS No.: 1394011-91-6
- Formule: C20H18ClF6N3O2
- Masse moléculaire:481.82
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Ferroptosis Compound Library
HY-L051
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) UC2288
More- Adv Sci (Weinh). 2025 Oct 5:e04474. [Abstract]
- J Biomed Sci. 2026 May 9;33(1):49. [Abstract]
- J Control Release. 2025 Nov 30:389:114488. [Abstract]
- Cell Rep Med. 2025 Feb 3:101964. [Abstract]
- Cell Death Dis. 2024 Jun 17;15(6):422. [Abstract]
- J Periodontal Res. 2024 Jun;59(3):599-610. [Abstract]
- J Oral Biosci. 2024 Sep 6:S1349-0079(24)00198-1. [Abstract]
- Res Sq. 2024 Jul 29.
- University of Gothenburg. 2023 Jun 27.
Customer Validation & Images
-
Cell Imaging/Staining
Activité biologique
UC2288 (0-10 μM; 24 hours) decreases p21 protein level, but has no effects on other proteins[1].UC2288 (0-10 μM; 24 hours) decreases p21 mRNA expression transcriptionally or post-transcriptionally but independently of p53[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HK2 (normal kidney), 786-O (RCC), Caki-1 (RCC), ACHN (RCC) and HEY (ovarian cancer) cells
-
Concentration:0 μM; 1 μM; 3 μM; 10 μM
-
Incubation Time:24 hours
-
Result:Decreased p21 protein expression.
-
Cell Line:p53-mutant RCC cell line 786-O
-
Concentration:10 μM
-
Incubation Time:24 hours
-
Result:Decreased p21 mRNA independent of p53 expression.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Eight-week old, athymic nude (NCr nu/nu) mice injected subcutaneously with HCT116 and ACHN cancer cells(2.5x106)[2]
-
Dosage:15 mg/kg
-
Administration:Oral gavage; 3 times a week; 4 weeks; co-treatment with imetelstat
-
Result:Combined treatment with imetelstat synergistically inhibited tumor growth in mice.
-
Animal Model:MPTP-induced C57BL6 Parkinson’s disease mice model[3]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; 4 times in 7 days
-
Result:Ameliorated MPTP induced PD progression through inhibition of neuroinammation.
Chemical Information
-
CAS No. 1394011-91-6
-
Appearance Solid
-
Masse moléculaire 481.82
-
Formule C20H18ClF6N3O2
-
Color White to off-white
-
SMILES
O=C(N[C@H]1CC[C@H](OC2=NC=C(C(F)(F)F)C=C2)CC1)NC3=CC=C(Cl)C(C(F)(F)F)=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
2025 Oct 5:e04474. PMID: 41047496 -
J Biomed Sci
CASK promotes non-small cell lung cancer growth through coordinated regulation of EGFR expression, trafficking, and p21 expression. [Abstract]2026 May 9;33(1):49. PMID: 42106797 -
J Control Release
Bioswitchable intracellular delivery of small activating RNA by tetrahedral framework nucleic acid: Application to p21-mediated anti-tumor therapy. [Abstract]2025 Nov 30:389:114488. PMID: 41330514 -
Cell Rep Med
Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies. [Abstract]2025 Feb 3:101964. PMID: 39933527
UC2288 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Feb 3:101964. [Abstract]
An increase in p21-positive PASMCs was observed with Barasertib treatment, which was attenuated by co-treatment with UC2288. In addition, cleaved caspase-3 staining revealed a significant increase in PASMC apoptosis after combination therapy.
-
Cell Death Dis
TGF-β1 facilitates gallbladder carcinoma metastasis by regulating FOXA1 translation efficiency through m6A modification. [Abstract]2024 Jun 17;15(6):422. PMID: 38886389 -
J Periodontal Res
ZNF862 induces cytostasis and apoptosis via the p21-RB1 and Bcl-xL-Caspase 3 signaling pathways in human gingival fibroblasts. [Abstract]2024 Jun;59(3):599-610. PMID: 38482719 -
J Oral Biosci
Antihypertensive agent losartan promotes tongue squamous cell carcinoma cell proliferation via EGFR/ERK1/2/cyclin D1 signaling axis. [Abstract]2024 Sep 6:S1349-0079(24)00198-1. PMID: 39245205 -
-
Solvant et solubilité
DMSO : 50 mg/mL (103.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 12.5 mg/mL (25.94 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hiromi I Wettersten, et al. A Novel p21 Attenuator Which Is Structurally Related to Sorafenib. Cancer Biol Ther. 2013 Mar;14(3):278-85. [Content Brief]
[2]. Romi Gupta, et al. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3062-71. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.0755 mL | 10.3773 mL | 20.7546 mL | 51.8866 mL |
| 5 mM | 0.4151 mL | 2.0755 mL | 4.1509 mL | 10.3773 mL | |
| 10 mM | 0.2075 mL | 1.0377 mL | 2.0755 mL | 5.1887 mL | |
| 15 mM | 0.1384 mL | 0.6918 mL | 1.3836 mL | 3.4591 mL | |
| 20 mM | 0.1038 mL | 0.5189 mL | 1.0377 mL | 2.5943 mL | |
| 25 mM | 0.0830 mL | 0.4151 mL | 0.8302 mL | 2.0755 mL | |
| DMSO | 30 mM | 0.0692 mL | 0.3459 mL | 0.6918 mL | 1.7296 mL |
| 40 mM | 0.0519 mL | 0.2594 mL | 0.5189 mL | 1.2972 mL | |
| 50 mM | 0.0415 mL | 0.2075 mL | 0.4151 mL | 1.0377 mL | |
| 60 mM | 0.0346 mL | 0.1730 mL | 0.3459 mL | 0.8648 mL | |
| 80 mM | 0.0259 mL | 0.1297 mL | 0.2594 mL | 0.6486 mL | |
| 100 mM | 0.0208 mL | 0.1038 mL | 0.2075 mL | 0.5189 mL |
Powered by Bioz